October 22, 2021 - By conducting data analytics on one of the world’s largest integrated health record databases, the Clalit Research Institute and Harvard University researchers examined the effectiveness of the Pfizer/BioNTech vaccine against the COVID-19 Delta variant among adolescents.

According to researchers, their study provides the most extensive peer-reviewed evaluation of the COVID-19 vaccine among adolescents in a nationwide mass-vaccination setting. Additionally, it is the first such study where the Delta variant was dominant.

It should be noted this study was conducted in Israel. However, due to the continued spread worldwide of the Delta variant, it could provide critical insights to public health officials around the globe.

Dig Deeper
Data Analytics, Artificial Intelligence Lower Hospital Infections
Improving COVID-19 Vaccine Outreach with Data Analytics, EHRs
Using Predictive Analytics to Determine COVID-19 Severity in Children
According to the press release, “The results of this study validate and complement the previously reported findings of a Pfizer/BioNTech Phase-III randomized clinical trial, which focused on symptomatic infections in the face of non-Delta variants, and which, with 1,983 vaccinated adolescents between the ages of 12 and 15 years, could not precisely assess vaccine effectiveness.”

https://healthitanalytics.com/news/data-analytics-evaluates-covid-19-vaccine-effectiveness